Copyright
©The Author(s) 2022.
World J Hepatol. Jul 27, 2022; 14(7): 1344-1356
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1344
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1344
Figure 4 Decision-making algorithm and key evaluation criteria for eligibility for alfapump® implantation.
MELD: Model for end-stage liver disease; TIPS: Transjugular intrahepatic portosystemic shunt.
- Citation: Weil-Verhoeven D, Di Martino V, Stirnimann G, Cervoni JP, Nguyen-Khac E, Thévenot T. Alfapump® implantable device in management of refractory ascites: An update. World J Hepatol 2022; 14(7): 1344-1356
- URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1344.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1344